Update and Future Directions in the Pharmacological Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)

LeBlanc, Pierre
June 2001
Clinical & Investigative Medicine;Jun2001 Supplement, Vol. 24, pS13
Academic Journal
The article presents update and discusses the future directions in the pharmacological treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is characterized by a progressive development of airflow limitation that is not fully reversible. Its incidence is increasing worldwide and there is a need to develop new treatments to prevent the progression of the disease which results in a large consumption of health care resources.


Related Articles

  • ExhaIed breath: can we identify inflammation?  // Thorax;Dec2003 Supplement 3, Vol. 58, piii35 

    Airway inflammation has a central role in the development and progression of chronic obstructive pulmonary disease (COPD) and bronchiectasis. Both pro-and anti-inflammatory mediators may control the inflammaibry response in airway disease. The aim of the study was to measure inflammatory...

  • Short Term Effects of Tiotropium on COPD Patients Treated with Long Acting Bronchodilators. Nicolini, Antonello // Tanaffos;2012, Vol. 11 Issue 1, p26 

    Background: The results of bronchodilator therapy in chronic obstructive pulmonary disease (COPD) are not satisfactory and because of this, many drugs are administered for treatment of disease. We examined the short-term additive bronchodilator effects of tiotropium in patients with stable COPD...

  • Meanings of being old and living with chronic obstructive pulmonary disease. Carling Elofsson, Linnéa; Öhlén, Joakim // Palliative Medicine;Nov2004, Vol. 18 Issue 7, p611 

    The aim of this study was to achieve a deeper understanding of the meaning of the lived experiences of elderly persons who are severely ill with chronic obstructive pulmonary disease (COPD) and in need of everyday care. Narratives from dialogues with six persons were interpreted using...

  • Patients with COPD: do we fail them from beginning to end? Partridge, M.R. // Thorax;May2003, Vol. 58 Issue 5, p373 

    Editorial. Recognizes the burden of chronic obstructive pulmonary disease (COPD) to both the individual and the society. Development of a comprehensive approach for the prevention and control of respiratory disease; Importance of diagnosing COPD early in its natural history.

  • Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Mannino, D.M.; Buist, A.S.; Petty, T.L.; Enright, P.L.; Redd, S.C. // Thorax;May2003, Vol. 58 Issue 5, p388 

    Background: A study was undertaken to define the risk of death among a national cohort of US adults both with and without lung disease.Methods: Participants in the first National Health and Nutrition Examination Survey (NHANES I) followed for up to 22 years were...

  • Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Brusasco, V.; Hodder, R.; Miravitlles, M.; Korducki, L.; Towse, L.; Kesten, S. // Thorax;May2003, Vol. 58 Issue 5, p399 

    Background: A study was undertaken to record exacerbations and health resource use in patients with COPD during 6 months of treatment with tiotropium, salmeterol, or matching placebos.Methods: Patients with COPD were enrolled in two 6-month randomised, placebo...

  • COPD: Management of Acute Exacerbation and Chronic Stable Disease. Hunter, Melissa H.; King, Dana E. // American Family Physician;8/15/2001, Vol. 64 Issue 4, p603 

    Acute exacerbations of chronic obstructive pulmonary disease (COPD) are treated with oxygen (in hypoxemic patients), inhaled beta2 agonists, inhaled anticholinergics, antibiotics and systemic corticosteroids. Methylxanthine therapy may be considered in patients who do not respond to other...

  • End-stage COPD. Fernandes, Tanya // Nursing Standard;10/10/2012, Vol. 27 Issue 6, p58 

    A quiz on end stage chronic obstructive pulmonary disease is presented.

  • Ultrafine Particles in Human Lung Macrophages. Hauser, Russ; Godleski, John J.; Hatch, Victoria; Christiani, David C. // Archives of Environmental Health;Mar/Apr 2001, Vol. 56 Issue 2, p150 

    ABSTRACT. As knowledge about size dependency of particle toxicity continues to grow, attention has been focused on ultrafine particles (i.e., < 0.1 micro m in diameter). In recent studies with rats, investigators learned that ultrafine particles likely have greater pulmonary toxicity than larger...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics